Cingulate (CING)

• Market cap: $64.6M
• 1 day: 0.76%
• 5 days: -2.04%
• 1 month: -9.91%
• 3 months: -27.01%
• 6 months: 45.18%
• Year to date: 20.32%
• 1 year: 28.85%
• 5 years: -99.51%
• 10 years: -99.51%
• Sector: Healthcare
• Industry: Biotechnology

About: Cingulate Inc is a clinical-stage biopharmaceutical company focused on the development of products utilizing its drug delivery platform technology that enables the formulation and manufacture of once-daily tablets of multi-dose therapies, with an initial focus on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD) and anxiety. The Company is developing two proprietary, first-line stimulant medications, CTx-1301 (dexmethylphenidate) and CTx-1302 (dextroamphetamine), for the treatment of ADHD intended for all patient segments: children, adolescents, and adults. The company focuses on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD) and anxiety, and identifying and evaluating additional therapeutic areas to use PTR technology to develop future product candidates.

Employees: 14